BIONCaRT
Latest round
- Seed
Last raised
- Aug 2024
Total raised
- Undisclosed
Investors
- 2
About BIONCaRT
Founded in 2017, BIONCaRT GmbH specializes in biopharmaceutical innovations, focusing on cell-based therapies derived from mesenchymal stromal cells (MSCs). The company has completed one deal, with its most recent transaction occurring on August 14, 2024.BIONCaRT GmbH specializes in the development and manufacture of biopharmaceuticals, primarily focusing on cell-based therapeutic products derived from mesenchymal stromal cells (MSCs) for clinical applications in humans. The company's flagship product, MesemCart, is an allogeneic cell therapy aimed at treating focal cartilage defects in the knee joint. This innovative therapy utilizes MSCs harvested from the umbilical cord tissue of healthy newborns, which are ex vivo expanded and embedded in a collagen-based matrix. The treatment aims to promote cartilage repair, reduce inflammation, and alleviate pain, addressing significant unmet medical needs for patients suffering from moderate to severe cartilage damage.The revenue model for BIONCaRT GmbH is principally structured around B2B transactions, focusing on partnerships with healthcare providers and institutions for the distribution of its therapeutic products. The company engages in clinical studies to validate the efficacy and safety of its offerings, which subsequently support the marketing authorization applications. Given the specialized nature of its flagship product, MesemCart, revenue generation is facilitated through fixed-price agreements or contracts with hospitals and clinics that participate in clinical trials and subsequent procurement of approved products. BIONCaRT GmbH's strategic plan includes the upcoming launch of MesemCart, targeting the German market in 2027 and expanding into broader European markets following the completion of Phase III trials.
Who invested in BIONCaRT
2 investors across 1 round
See all investors in BIONCaRT
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Aug 14, 2024
Amount
Undisclosed
Investors
Questions about BIONCaRT
Who invested in BIONCaRT?
BIONCaRT has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BIONCaRT raised?
BIONCaRT has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BIONCaRT last raise money?
BIONCaRT's most recent round on record is a Seed, in Aug 2024.
What does BIONCaRT do?
Founded in 2017, BIONCaRT GmbH specializes in biopharmaceutical innovations, focusing on cell-based therapies derived from mesenchymal stromal cells (MSCs).
Where is BIONCaRT headquartered?
BIONCaRT is headquartered in Leipzig, Germany.
Which VCs invest in companies like BIONCaRT?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at BIONCaRT's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like BIONCaRT? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.